Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 Combined With Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
NCT07720193Phase 3Not yet recruiting
- Sponsor
- Leads Biolabs
- Start
- Nov 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
A Phase 3 trial of opamtistomig in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Leads Biolabs. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
opamtistomig
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT07720193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07720193.